Raja-Elie E Abdulnour1, Tina Gunderson2, Ioanna Barkas1, Jack Y Timmons1, Cindy Barnig1,3, Michelle Gong4,5, Daryl J Kor6, Ognjen Gajic7, Daniel Talmor8, Rickey E Carter2, Bruce D Levy1. 1. 1 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. 2 Division of Biomedical Statistics and Informatics, Department of Health Sciences Research. 3. 3 Department of Chest Disease, University Hospital of Strasbourg and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France. 4. 4 Department of Medicine and. 5. 5 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Montefiore Healthcare Center, Bronx, New York; and. 6. 6 Department of Anesthesiology and Perioperative Medicine, and. 7. 7 Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota. 8. 8 Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Abstract
RATIONALE: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies. OBJECTIVES: To determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS. METHODS: Patients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B2 (TXB2), aspirin-triggered lipoxin A4 (15-epi-LXA4, ATL), and peripheral blood leukocyte number and activation were determined on enrollment and after treatment with either aspirin or placebo. MEASUREMENTS AND MAIN RESULTS: Thirty-three of 367 subjects (9.0%) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB2 and increased the ATL/TXB2 ratio. CONCLUSIONS: Biomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk. Clinical trial registered with www.clinicaltrials.gov (NCT01504867).
RATIONALE: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies. OBJECTIVES: To determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS. METHODS: Patients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B2 (TXB2), aspirin-triggered lipoxin A4 (15-epi-LXA4, ATL), and peripheral blood leukocyte number and activation were determined on enrollment and after treatment with either aspirin or placebo. MEASUREMENTS AND MAIN RESULTS: Thirty-three of 367 subjects (9.0%) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB2 and increased the ATL/TXB2 ratio. CONCLUSIONS: Biomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk. Clinical trial registered with www.clinicaltrials.gov (NCT01504867).
Authors: Susanne Herold; Tannaz Shafiei Tabar; Hermann Janssen; Katrin Hoegner; Maciej Cabanski; Peter Lewe-Schlosser; Jens Albrecht; Frank Driever; Istvan Vadasz; Werner Seeger; Mirko Steinmueller; Juergen Lohmeyer Journal: Am J Respir Crit Care Med Date: 2011-01-28 Impact factor: 21.405
Authors: Ognjen Gajic; Ousama Dabbagh; Pauline K Park; Adebola Adesanya; Steven Y Chang; Peter Hou; Harry Anderson; J Jason Hoth; Mark E Mikkelsen; Nina T Gentile; Michelle N Gong; Daniel Talmor; Ednan Bajwa; Timothy R Watkins; Emir Festic; Murat Yilmaz; Remzi Iscimen; David A Kaufman; Annette M Esper; Ruxana Sadikot; Ivor Douglas; Jonathan Sevransky; Michael Malinchoc Journal: Am J Respir Crit Care Med Date: 2010-08-27 Impact factor: 21.405
Authors: Katie R Famous; Kevin Delucchi; Lorraine B Ware; Kirsten N Kangelaris; Kathleen D Liu; B Taylor Thompson; Carolyn S Calfee Journal: Am J Respir Crit Care Med Date: 2017-02-01 Impact factor: 21.405
Authors: Emiko Ono; Stefanie Dutile; Shamsah Kazani; Michael E Wechsler; Jun Yang; Bruce D Hammock; David Nobuhiro Douda; Yacine Tabet; Rayan Khaddaj-Mallat; Marco Sirois; Chantal Sirois; Edmond Rizcallah; Eric Rousseau; Richard Martin; E Rand Sutherland; Mario Castro; Nizar N Jarjour; Elliot Israel; Bruce D Levy Journal: Am J Respir Crit Care Med Date: 2014-10-15 Impact factor: 21.405
Authors: Dominick J H McCabe; Paul Harrison; Ian J Mackie; Paul S Sidhu; Gordon Purdy; Andrew S Lawrie; Hilary Watt; Martin M Brown; Samuel J Machin Journal: Br J Haematol Date: 2004-06 Impact factor: 6.998
Authors: R E Abdulnour; H P Sham; D N Douda; R A Colas; J Dalli; Y Bai; X Ai; C N Serhan; B D Levy Journal: Mucosal Immunol Date: 2015-12-09 Impact factor: 7.313
Authors: Jeffrey S Berger; Lucy Z Kornblith; Michelle N Gong; Harmony R Reynolds; Mary Cushman; Yu Cheng; Bryan J McVerry; Keri S Kim; Renato D Lopes; Bassel Atassi; Scott Berry; Grant Bochicchio; Murillo de Oliveira Antunes; Michael E Farkouh; Yonatan Greenstein; Erinn M Hade; Kristin Hudock; Robert Hyzy; Pooja Khatri; Andrei Kindzelski; Bridget-Anne Kirwan; Lisa Baumann Kreuziger; Patrick R Lawler; Eric Leifer; Jose Lopez-Sendon Moreno; Jose Lopez-Sendon; James F Luther; Lilia Nigro Maia; John Quigley; Robert Sherwin; Lana Wahid; Jennifer Wilson; Judith S Hochman; Matthew D Neal Journal: JAMA Date: 2022-01-18 Impact factor: 157.335
Authors: Michael A Matthay; Rachel L Zemans; Guy A Zimmerman; Yaseen M Arabi; Jeremy R Beitler; Alain Mercat; Margaret Herridge; Adrienne G Randolph; Carolyn S Calfee Journal: Nat Rev Dis Primers Date: 2019-03-14 Impact factor: 52.329
Authors: Brijesh V Patel; Deepa J Arachchillage; Carole A Ridge; Paolo Bianchi; James F Doyle; Benjamin Garfield; Stephane Ledot; Cliff Morgan; Maurizio Passariello; Susanna Price; Suveer Singh; Louit Thakuria; Sarah Trenfield; Richard Trimlett; Christine Weaver; S John Wort; Tina Xu; Simon P G Padley; Anand Devaraj; Sujal R Desai Journal: Am J Respir Crit Care Med Date: 2020-09-01 Impact factor: 21.405
Authors: Bakr Jundi; Hyunryul Ryu; Do-Hyun Lee; Raja-Elie E Abdulnour; Braden D Engstrom; Melody G Duvall; Angelica Higuera; Mayra Pinilla-Vera; Maura E Benson; Jaemyon Lee; Nandini Krishnamoorthy; Rebecca M Baron; Jongyoon Han; Joel Voldman; Bruce D Levy Journal: Nat Biomed Eng Date: 2019-11-11 Impact factor: 25.671